It is generally accepted that solanaceous alkaloids are effective in the symptomatic treatment of Parkinson's syndrome but that none of them is entirely satisfactory. There is no agreement, however, as to the comparative value of the individual alkaloids and their combinations. The well known suggestibility of patients with this syndrome renders such comparative studies difficult and has actually misled many investigators.Nevertheless, most clinicians admit the superiority of Roemer's1 treatment with massive doses of atropine and of the so-called Bulgarian treatment.2 Different as the two therapeutic methods are qualitatively, they have in common the same quantitative principle: the use of large doses approaching the limit of toxicity. After Bremer's3 observation that an unusually high tolerance to atropine exists in cases of chronic encephalitis, Roemer1 concluded that massive doses are required for patients with this disease. His therapeutic experiments were highly successful and his results
VOLLMER H. COMPARATIVE VALUE OF SOLANACEOUS ALKALOIDS IN TREATMENT OF PARKINSON'S SYNDROME. Arch NeurPsych. 1942;48(1):72–84. doi:10.1001/archneurpsyc.1942.02290070082006
Customize your JAMA Network experience by selecting one or more topics from the list below.